Synthesis and mixed lineage kinase activity of pyrrolocarbazole and isoindolone analogs of (+)K-252a

Journal of Medicinal Chemistry

Volumn 50, Issue 3, 2007, Pages 433-441

  Hudkins, Robert L ^a   Johnson, Neil W ^a   Angeles, Thelma S ^a   Gessner, George W ^a   Mallamo, John P ^a  

^a CEPHALON INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

12,13 DIHYDRO 5H,6H,14H NAPHTHYL[3,4 A]PYRROLO[3,4 C]CARBAZOL 7(7H) ONE; 12,13 DIHYDRO 6H,14H NAPHTHYL[3,4 A]PYRROLO[3,4 C]CARBAZOL 5,7(5H,7H) DIONE; AGLYCONE; CARBAZOLE DERIVATIVE; CEP 1347; ENZYME INHIBITOR; HETEROCYCLIC COMPOUND; INDOLE DERIVATIVE; ISOINDOLONE DERIVATIVE; K 252A; LACTAM; MIXED LINEAGE KINASE; MIXED LINEAGE KINASE 1; MIXED LINEAGE KINASE 3; NATURAL PRODUCT; NITROGEN; PYRROLOCARBAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CHO CELL; CONTROLLED STUDY; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVITY; NONHUMAN; STEREOCHEMISTRY;

ANIMALS; CARBAZOLES; CHO CELLS; CRICETINAE; CRICETULUS; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; INDOLES; MAP KINASE KINASE KINASES; MODELS, MOLECULAR; PYRROLES; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33846936741     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm051074u     Document Type: Article

References (47)

1. (a) Hirsch, E. C.; Hunot, S.; Faucheux, B.; Agid, Y.; Mizuno, Y.; Mochizuki, H.; Tatton, W. G.; Tatton, N.; Olanow, W. C. Dopaminergic neurons degenerate by apoptosis in Parkinson's disease. Mov. Discord. 1999, 14, 383-385.
2. (b) Hartman, A.; Hunot, S.; Michel, P. P.; Muriel, M. P.; Vyas, S.; Faucheux, B.; Mouatt-Prigent, A.; Turmel, H.; Srinivasan, A.; Ruberg, M.; Evan, G. I.; Agid, Y.; Hirsch, E. C. Caspase-3: A vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson's disease. Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 2875-2880.
3. (c) Anderson, A. J.; Su, J. H.; Cotman, C. W. DNA damage and apoptosis in Alzheimer's disease: colocalization with c-Jun immunoreactivity, relationship to brain area, and effect of postmortem delay. J. Neurosci. 1996, 16, 1710-1719.
4. (a) Bozyczko-Coyne D.; Saporito, M. S.; Hudkins, R. L. Targeting the JNK pathway for therapeutic benefit in CNS disease. Curr. Drug Targets: CNS Neurol. Disord. 2002, 1, 31-49.
5. (b) Bogoyevitch, M. A.; Boehm, I.; Oakley, A.; Ketterman, A. J.; Barr, R. K. Targeting the JNK MAPK cascade for inhibition: basic science and therapeutic potential. Biochim. Biophys. Acta 2004, 1697, 89-101.
6. (c) Manning, A. M.; Davis, R. J. Targeting JNK for therapeutic benefit: from junk to gold? Nat. Rev. Drug Discovery 2003, 2, 554-564.
7. (d) Harper, S. J.; LoGrasso, P. Signaling for survival and death in neurons. The role of stress-activated kinases, JNK and p38. Cell. Signalling 2001, 13, 299-310.
8. (e) Mielke, K.; Herdegen, T. JNK and p28 stress kinases - degenerative effectors of signal-transduction-cascades in the nervous system. Prog. Neurobiol. 2000, 61, 45-60.
9. (a) Gupta, S.; Barrett, T.; Whitmarsh, A. J.; Cavanagh, J.; Sluss, H. K.; Derijard, B.; Davis, R. J. Selective interaction of JNK protein kinase isoforms with transcription factors. EMBO J. 1996, 15, 2760-2770.
10. (b) Kallunki, T.; Su, B.; Tsigelny, I. Sluss, H. K.; Derijard, B.; Moore, G.; Davis, R.; Karin, M. JNK2 contains a specificity-determining region responsible for efficient c-Jun binding and phosphorylation. Genes Dev. 1994, 8, 2996-3007.
11. (c) Kallunki, T.; Deng, T.; Hibi, M.; Karin, M. c-Jun can recruit JNK to phosphorylate dimerization partners via specific docking interactions. Cell 1996, 87, 1-20.
12. (a) Maroney, A. C.; Saporito, M. A.; Hudkins, R. L. Mixed lineage kinase family, potential targets for preventing neurodegeneration. Curr. Med. Chem: Cent. Nerv. Syst. Agents 2002, 2, 143-155.
13. (b) Wang, L. H.; Besirli, C. G.; Johnson, E., Jr. Mixed lineage kinases: A target for the prevention of neurodegeneration. Annu. Rev. Pharmacol. Toxicol. 2004, 44, 451-474.
14. (c) Gallo, K. A.; Johnson, G. L. Mixed-lineage kinase control of JNK and p38 MAPK pathways. Nat. Rev. Mol. Biol. 2002, 3, 663-672.
15. (a) Xu, Z.; Maroney, A. C.; Dobrzanski, P.; Kukekov, N. V.; Greene, L. A. The MLK family mediates c-Jun N-terminal kinase activation in neuronal apoptosis. Mol. Cell Biol. 2001, 21, 4713-4724.
16. (b) Mota, M.; Reeder, M.; Chernoff, J.; Bazenet, C. E. Evidence for a role of mixed lineage kinases in neuronal apoptosis. J. Neurosci. 2001, 21, 4949-4957.
17. Murakata, C.; Kaneko, M.; Gessner, G.; Angeles, T. S.; Ator, M. A.; O'Kane, T. M.; McKenna, B. A. W.; Thomas, B. A.; Mathiasen, J. R.; Saporito, M. S.; Bozyczko-Coyne, D.; Hudkins, R. L. Mixed Lineage kinase activity of indolocarbazole analogs. Bioorg. Med. Chem. Lett. 2002, 12, 147-150.
18. (a) Saporito, M. A.; Hudkins, R. L.; Maroney, A. C. Discovery of CEP-1347/KT-7515: An inhibitor of the cJun N-terminal kinase pathway for the treatment of neurodegenerative diseases. Prog. Med. Chem. 2002, 40, 23-62.
19. (b) Glicksman, M. A.; Chiu, A. Y.; Dionne, C. A.; Kaneko, M.; Murakata, C.; Oppenheim, R. W.; Prevette, D.; Sengelaub, D. R.; Vaught, J. L.; Neff, N. T. CEP-1347/KT7515 prevents motor neuronal programmed cell death and injury-induced dedifferentiation in vivo. J. Neurobiol. 1998, 35, 361-370.
20. (c) Borasio, G. D.; Hostmann, S.; Anneser, J. M. H.; Neff, N. T.; Glicksman, M. A. CEP-1347/KT7515, a JNK pathway inhibitor, supports the in vitro survival of chick embryonic neurons. NeuroReport 1998, 9, 1435-1439.
21. Maroney, A. C.; Finn, J. P.; Connors, T. J.; Durkin, J. T.; Angeles, T.; Gessner, G.; Xu, Z.; Meyer, S. L.; Savage, M. J.; Greene, L. A.; Scott, R. W.; Vaught, J. L. CEP-1347 (KT-7515), a semisynthetic inhibitor of the mixed lineage kinase family. J. Biol. Chem. 2001, 276, 25302-25308.
22. (a) Saporito, M. S.; Brown, E. M.; Miller, M. S.; Carswell, S. CEP-1347/KT7515, an inhibitor of c-Jun N-terminal kinase activation, attenuates the 1-methyl-4-phenyl tetrahydropyridine-mediated loss of nigrostriatal dopaminergic neurons in vivo. J. Pharmacol. Exp. Ther. 1999, 288, 421-427.
23. 2-terminal kinase (JNK) and its upstream regulator kinse MKK4 in nigrostriatal neurons in vivo. J. Neurochem. 2000, 75, 1200-1208.
24. Kaneko, M.; Saito, Y.; Saito, H.; Matsumoto, T.; Matsuda, Y.; Vaught, J. L.; Dionne, C. A.; Angeles, T. S.; Glicksman, M. A.; Neff, N. T.; Rotella, D. P.; Kauer, J. C.; Mallamo, J. P.; Hudkins, R. L.; Murakata, C. Neurotrophic 3,9-bis[(alkylthiomethyl]- and -[bis-(alkoxymethyl)]-K-252a Derivatives. J. Med. Chem. 1997, 40, 1863-1869.
25. Kase, H.; Iwahashi, K.; Matsuda, Y. K-252a, a potent inhibitor of protein kinase C from microbial origin. J. Antibiot. 1986, 39, 1059-1065.
26. Nakanishi, S.; Matsuda, K.; Iwahashi, K.; Kase, H. K-252b, c and d, potent inhibitors of protein kinase C from microbial origin. J. Antibiot. 1986, 39, 1066-1071.
27. Schiering, N.; Knapp, S.; Marconi, M.; Flocco, M. M.; Cui, J.; Perego, R.; Rusconi, L.; Cristiani, C. Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-Met and its complex with the microbial alkaloid K-252a. Proc. Natl. Acad. Sci. U.S.A. 2003, 22, 12654-12659.
28. Hudkins, R. L.; Park, C-H. Synthesis of indeno[2, 1-a]pyrrolo[3,4-c] carbazole lactam regioisomers using ethyl cis-β-cyanoacrylate as a dienophile and lactam precursor. J. Heterocycl. Chem. 2003, 40, 135-142.
29. Hudkins, R. L.; Johnson, N. W. Synthesis of benzo[b]thieno- and benzo[b]furano[2,3-a]pyrrolo[3,4-c]carbazole-5-, -7- and -5,7-dione. J. Heterocycl. Chem. 2001, 38, 591-595.
30. Baierweck, P.; Simmross, U.; Muellen, K. Biindenyls, biindenylides and diindeno-fused heterocycles from oxidative coupling of 1- and 2-indanone. Chem. Ber. 1988, 121, 2195-2200.
31. (a) Hudkins, R. L.; Johnson, N. W. Fused Isoindolones as Inhibitors, of PKC. U.S. Patent 5,705,511, 1997.
32. (b) Hudkins, R. L.; Johnson, N. W. Fused Isoindolones. U.S. Patent 5,808,060, 1998.
33. Lindley, W. A.; MacDowell, D. W. H. Keto-enol tautomerism in the thiophene analogs of naphthacen-5-one. J. Org. Chem. 1982, 47, 705-709.
34. Rotella, D. P.; Glicksman, M. A.; Pranter, J. E.; Neff, N. T.; Hudkins, R. L. The effect of pyrrolo[3,4-c]carbazole derivatives on spinal cord ChAT activity. Bioorg. Med. Chem. Lett. 1995, 5, 1167-1170.
35. Ator, M. A.; Chatterjee, S.; Bihovski, R.; Dunn; Hudkins, R. L. Multicyclic PARP and kinase inhibitors. WO0185686, 2001.
36. Hudkins, R. L.; Fused Isoindolones. U.S. Patent 6,399,780, 2005.
37. Gingrich, D. L.; Yang, S. X.; Gessner, G. W.; Angeles, T. S.; Hudkins, R. L. Synthesis, modeling and in vitro activity of 3′-(S)-epi- K-252a analogues. Elucidating the stereochemical requirements of the 3′-sugar alcohol on trkA tyrosine kinase activity. J. Med. Chem. 2005, 48, 3776-3783.
38. Ruggeri, B. A.; Miknyoczki, S. J.; Singh, J.; Hudkins, R. L.; The role of neurotrophin-trk interactions in oncology: The antitumor efficacy of potent and selective trk tyrosine kinase inhibitors on preclinical tumor models. Curr. Med. Chem. 1999, 6, 845-857.
39. (a) Glicksman, M. A.; Prantner, J. E.; Meyer, S. L.; Forbes, M. E.; Dasgupta, M.; Lewis, M. E.; Neff, N. T. K-252a and staurosporine promote choline acetyltransferase activity in rat spinal cord culture. J. Neurochem. 1993, 61, 210-221.
40. (b) Glicksman, M. A.; Forbes, M. E.; Prantner, J. E.; Neff, N. T. K-252a promotes survival and choline acetyltransferase activity in striatal and basal forebrain neuronal cultures. J. Neurochem. 1995, 64, 1502-1512.
41. Phelps, P. E.; Barber, R. P.; Vaughn, J. E. Generation patterns of four groups of cholinergic neurons in rat cervical spinal cord: a combined tritiated thymidine autoradiographic and choline acetyltransferase immunocytochemical study. J. Comp. Neurol. 1988, 273, 459-472.
42. (a) Hartikka, K. J.; Hefti, F. Development of septal cholinergic neurons in culture: plating density and glial cells modulate effects of NGF on survival, fiber growth and expression of transmitter-specific enzymes. J. Neurosci. 1988, 8, 2967-2985.
43. (b) Lewis, M. E.; Neff, N. T.; Contreras, P. C.; Stong, D. B.; Oppenheim, R. W.; Grebow, P. E.; Vaught, J. L. Insulin-like growth factor-I: potential for treatment of motor neuronal disorders. Exp. Neurol. 1993, 124, 73-88.
44. (c) Neff, N. T.; Prevette, D.; Houenou, L. J.; Lewis, M. E.; Glicksman, M. A.; Yin, Q. W.; Oppenheim, R. W. Insulin-like growth factors: Putative muscle derived trophic agents that promote motoneuron survival. J. Neurobiol. 1993, 24, 1578-1588.
45. Gingrich, D. E.; Reddy, D. R.; Iqbal, M. A.; Singh, J.; Aimone, L. D.; Angeles, T. S.; Albom, M.; Yang, S.; Meyer, S.; Robinson, C.; Ruggeri, B. A.;. Dionne, C. A.; Vaught, J. L.; Mallamo, J. P.; Hudkins, R. L. A new class of potent VEGF receptor tyrosine kinase inhibitors: Structure-activity relationships for a series of 9-alkoxymethyl-12-(3-hydroxypropyl)indeno[2,1-a] pyrrolo[3,4-c]carbazole-5-ones and the identification of CEP-5214 and its dimethylglycine ester prodrug clinical candidate CEP-7055. J. Med. Chem. 2003, 46, 5375-5388.
46. Angeles, T. S.; Steffler, C.; Bartlett, B. A.; Hudkins, R. L.; Stephens, R. M.; Kaplan, D. R.; Dionne, C. A. Enzyme linked immunosorbant assay for TrkA tyrosine kinase activity. Anal. Biochem. 1996, 236, 49-55.
47. Ruggeri, B.; Singh, J.; Gingrich, D.; Angeles, T.; Albom, M.; Chang, H.; Robinson, C.; Hunter, K.; Dobrzanski, P.; Jones-Bolin, S.; Aimone, L.; Klein-Szanto, A.; Herbert, J-M.; Bono, F.; Casellas, P.; Bourie, B.; Pili, R.; Isaacs, J.; Ator, M.; Hudkins, R.; Dionne, C.; Mallamo, J.; Vaught, J. CEP-7055: A novel, orally-active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent anti-angiogenic activity and anti-tumor efficacy in pre-clinical models. Cancer Res. 2003, 63, 5978-5991.